Generation of high-affinity CMV-specific T cells for adoptive immunotherapy using IL-2, IL-15, and IL-21
Copyright © 2020 Elsevier Inc. All rights reserved..
Cytomegalovirus (CMV) infection remains a life-threatening condition in individuals with a suppressed immune system. CMV may also represent a clinically relevant target for immune responses in CMV-positive malignancies. We established a protocol to expand CMV-specific T cells (CMV-T) using peripheral blood mononuclear cells (PBMCs). PBMCs from 16 HLA-A*0201 donors were cultured with a cytokine cocktail comprising IL-2/IL-15/IL-21 along with overlapping peptides from CMV-pp65. Ten days later, T cells were stimulated with anti-CD3 (OKT3) and irradiated autologous PBMCs. CMV-T were detected by HLA-A*0201 CMV-pp65NLVPMVATV wild type and q226a mutant tetramers (for high-affinity T cells), intracellular cytokine staining, a CD107a mobilization assays as well as IFN-γ and TNF-α production in cell culture supernatants. We reliably obtained 50.25 ± 27.27% of CD8+ and 22.08 ± 21.83% of CD4+ T cells post-CMV-pp65 stimulation of PBMCs with a Th1-polarized phenotype and decreased Th2/Th17 responses. Most CD3 + CD8 + tetramer+ T cells were effector-memory cells, particularly among high-affinity CMV-T (q226a CMV-tetramer+). High-affinity CMV-T cells, compared to WT-tetramer+ cells, expressed higher IL-21R and lower FasL post-stimulation with CMV-pp65. The IL-2/IL-15/IL-21 cocktail also promoted CCR6 and CXCR3 expression necessary for T-cell migration into tissues. We have optimized methods for generating high-affinity CMV-specific T cells that can be used for adoptive cellular therapy in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:217 |
|---|---|
| Enthalten in: |
Clinical immunology (Orlando, Fla.) - 217(2020) vom: 30. Aug., Seite 108456 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luo, Xiao-Hua [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2021 Date Revised 01.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clim.2020.108456 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309598796 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309598796 | ||
| 003 | DE-627 | ||
| 005 | 20231225134248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clim.2020.108456 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309598796 | ||
| 035 | |a (NLM)32376504 | ||
| 035 | |a (PII)S1521-6616(19)30509-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luo, Xiao-Hua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generation of high-affinity CMV-specific T cells for adoptive immunotherapy using IL-2, IL-15, and IL-21 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2021 | ||
| 500 | |a Date Revised 01.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Cytomegalovirus (CMV) infection remains a life-threatening condition in individuals with a suppressed immune system. CMV may also represent a clinically relevant target for immune responses in CMV-positive malignancies. We established a protocol to expand CMV-specific T cells (CMV-T) using peripheral blood mononuclear cells (PBMCs). PBMCs from 16 HLA-A*0201 donors were cultured with a cytokine cocktail comprising IL-2/IL-15/IL-21 along with overlapping peptides from CMV-pp65. Ten days later, T cells were stimulated with anti-CD3 (OKT3) and irradiated autologous PBMCs. CMV-T were detected by HLA-A*0201 CMV-pp65NLVPMVATV wild type and q226a mutant tetramers (for high-affinity T cells), intracellular cytokine staining, a CD107a mobilization assays as well as IFN-γ and TNF-α production in cell culture supernatants. We reliably obtained 50.25 ± 27.27% of CD8+ and 22.08 ± 21.83% of CD4+ T cells post-CMV-pp65 stimulation of PBMCs with a Th1-polarized phenotype and decreased Th2/Th17 responses. Most CD3 + CD8 + tetramer+ T cells were effector-memory cells, particularly among high-affinity CMV-T (q226a CMV-tetramer+). High-affinity CMV-T cells, compared to WT-tetramer+ cells, expressed higher IL-21R and lower FasL post-stimulation with CMV-pp65. The IL-2/IL-15/IL-21 cocktail also promoted CCR6 and CXCR3 expression necessary for T-cell migration into tissues. We have optimized methods for generating high-affinity CMV-specific T cells that can be used for adoptive cellular therapy in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adoptive immunotherapy | |
| 650 | 4 | |a CMV-specific T cells | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a IL-15 | |
| 650 | 4 | |a IL-2 | |
| 650 | 4 | |a IL-21 | |
| 650 | 7 | |a HLA-A*02:01 antigen |2 NLM | |
| 650 | 7 | |a HLA-A2 Antigen |2 NLM | |
| 650 | 7 | |a IFNG protein, human |2 NLM | |
| 650 | 7 | |a IL15 protein, human |2 NLM | |
| 650 | 7 | |a IL2 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-15 |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a interleukin-21 |2 NLM | |
| 650 | 7 | |a MKM3CA6LT1 |2 NLM | |
| 700 | 1 | |a Meng, Qingda |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhenjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Paraschoudi, Georgia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical immunology (Orlando, Fla.) |d 1999 |g 217(2020) vom: 30. Aug., Seite 108456 |w (DE-627)NLM098196855 |x 1521-7035 |7 nnns |
| 773 | 1 | 8 | |g volume:217 |g year:2020 |g day:30 |g month:08 |g pages:108456 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clim.2020.108456 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 217 |j 2020 |b 30 |c 08 |h 108456 | ||